Pfizer Taiwan

Pfizer Taiwan is a top-3 multinational pharma in Taiwan by revenue (alongside Roche, MSD/Merck). Established 1962 — one of the oldest MNC pharma operations in the country. Post-2019 Haleon spin-off, Pfizer Taiwan is now pure-play Rx pharma + vaccines, meaning consumer-facing advertising is SHARPLY LIMITED by Taiwan FDA regulations (Pharmaceutical Affairs Act 藥事法) which restrict Rx drug advertising to medical professionals only. Consumer brand spend is therefore: (a) corporate brand/PR campaigns, (b) disease-awareness campaigns (unbranded — diabetes, cardiovascular, oncology, rare disease awareness), (c) vaccine campaigns (Prevenar adult pneumonia awareness — heavy TW spend), (d) HCP marketing through specialist agencies. Overall paid-media footprint is mid-tier, NOT high — most spend is HCP/medical-channel, not consumer mass media.